Endpoint | Clinical parameter | Test-TMA cohort | Validation-TMA cohort | ||||||
---|---|---|---|---|---|---|---|---|---|
P | Exp(B) | 95.0% CI | P | Exp(B) | 95.0% CI | ||||
Lower | Upper | Lower | Upper | ||||||
BCR | Serum PSA level | < 0.001 | 1.064 | 1.042 | 1.086 | < 0.001 | 1.031 | 1.026 | 1.036 |
Gleason score at RP (6, 3 + 4, 4 + 3, > 8) | < 0.001 | 2.035 | 1.631 | 2.54 | < 0.001 | 1.946 | 1.778 | 2.13 | |
pTNM | < 0.001 | 4.673 | 3.133 | 6.97 | < 0.001 | 2.599 | 2.202 | 3.067 | |
Margin status | < 0.001 | 2.392 | 1.517 | 3.77 | < 0.001 | 2.362 | 1.955 | 2.852 | |
Bone metastasis | Serum PSA level | 0.051 | 1.047 | 1 | 1.096 | 0.047 | 1.018 | 1 | 1.036 |
Gleason score at RP (6, 3 + 4, 4 + 3, > 8) | 0.001 | 3.159 | 1.6 | 6.237 | < 0.001 | 3.333 | 2.476 | 4.487 | |
pTNM | < 0.001 | 8.396 | 3.043 | 23.162 | < 0.001 | 3.882 | 2.422 | 6.22 | |
Margin status | 0.125 | 2.624 | 0.765 | 9.008 | 0.988 | 0.996 | 0.569 | 1.743 | |
PC specific death | Serum PSA level | – | – | – | – | 0.046 | 1.02 | 1 | 1.039 |
Gleason score at RP (6, 3 + 4, 4 + 3, > 8) | 0.001 | 3.159 | 1.6 | 6.237 | < 0.001 | 3.333 | 2.476 | 4.487 | |
pTNM | – | – | – | – | < 0.001 | 3.263 | 1.843 | 5.78 | |
Margin status | – | – | – | – | 0.117 | 1.689 | 0.877 | 0.3252 |